- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03878446
Une étude de recherche chez les enfants nés petits et qui sont restés petits. Le traitement est Somapacitan une fois par semaine par rapport à Norditropin® une fois par jour
Un essai de recherche de dose évaluant l'effet et l'innocuité d'un traitement une fois par semaine au somapacitan par rapport à une prise quotidienne de Norditropin® chez les enfants de petite taille nés petits pour l'âge gestationnel sans rattrapage de croissance à l'âge de 2 ans ou plus
The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Algiers, Algérie, 16000
- CHU Bab El Oued Pediatrics Dept
-
Algiers, Algérie, 16000
- Endo and Diab Dept El Oued
-
Constantine, Algérie, 25000
- endocrino-diabetology department, Hospital IBN BADIS.
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Stollery Children's Hospital
-
-
-
-
-
Copenhagen Ø, Danemark, 2100
- Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
-
-
-
-
-
Esplugues Llobregat(Barcelona), Espagne, 08950
- Hospital Sant Joan de Déu
-
Santiago de Compostela, Espagne, 15706
- Hospital Clínico de Santiago de Compostela
-
-
-
-
-
Tallinn, Estonie, 13419
- Tallinn Children's Hospital
-
Tartu, Estonie, 50406
- Tartu University Hospital Children's Clinic
-
-
-
-
-
Angers, France, 49100
- Centre Hospitalier Universitaire D'Angers-2
-
Le Kremlin-Bicêtre, France, 94270
- AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
-
Marseille, France, 13005
- Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
-
Marseille Cédex 05, France, 13385
- Hopital de La Timone
-
Paris, France, 75015
- Ap-Hp-Hopital Necker
-
Paris, France, 75015
- Hôpital Necker
-
Toulouse, France, 31059
- HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
-
-
-
-
-
Budapest, Hongrie, 1023
- Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
-
Szeged, Hongrie, 6720
- Szegedi Tudományegyetem Gyermekgyógyászati Klinika
-
-
-
-
Kerala
-
Kochi, Kerala, Inde, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Maharashtra
-
Pune, Maharashtra, Inde, 411001
- Jehangir Clinical Development Centre
-
-
New Delhi
-
New Dehli, New Delhi, Inde, 110029
- All India Institute of Medical Sciences
-
-
-
-
-
Dublin, Irlande, D12 N512
- CHI Crumlin Dept of Endocrinology
-
-
-
-
-
Haifa, Israël, 31096
- Rambam MC - Department of Pediatrics A
-
Kfar Saba, Israël, 44281
- Meir MC - Department of Paediatrics
-
Petah Tikva, Israël, 49202
- Schneider MC - Endrocrinology and Diabetes
-
-
-
-
-
Florence, Italie, 50139
- IRCCS Meyer Firenze
-
Genova, Italie, 16147
- Ospedale Pediatrico Gaslini
-
Milan, Italie, 20122
- Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
-
Roma, Italie, 00165
- Ospedale Pediatrico Bambino Gesu
-
-
-
-
-
Fukuoka, Japon, 830-0011
- Kurume University Hospital, Pediatrics
-
Fukuoka-shi, Fukuoka, Japon, 813-0017
- Fukuoka Children's Hospital_Endocrinology and Metabolism
-
Fukuoka-shi, Fukuoka, Japon, 813-0017
- Fukuoka Children's Hospital
-
Fukuyama-shi, Hiroshima, Japon, 721-8511
- Fukuyama City Hospital_Department of Pediatrics
-
Kobe-shi, Hyogo, Japon, 650-0047
- Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
-
Kobe-shi, Hyogo, Japon, 650-0047
- Hyogo Prefectual Kobe Children's Hospital_Metab & endo
-
Kyoto, Japon, 602-8566
- Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
-
Nara-shi, Nara, Japon, 630-8581
- Nara Prefecture General Medical Center_ Nara-shi, Nara
-
Nara-shi, Nara, Japon, 630-8581
- Nara Prefecture General Medical Center_Pediatric
-
Niigata-shi, Niigata, Japon, 951 8520
- Niigata University Medical & Dental Hospital_Pediatrics
-
Osaka, Japon, 534-0021
- Osaka City General Hospital, Pediatric Endocrinology and Me
-
Osaka, Japon, 594-1101
- Osaka Women's and Children's Hospital
-
Saitama-shi, Saitama, Japon, 330-8777
- Saitama Children's Medical Center, Endocrinorogy&Metabolism
-
Tokyo, Japon, 157 8535
- National Center for Child Health and Dev, Endo and Metabo
-
Tokyo, Japon, 113-8519
- Institute of Science Tokyo Hospital
-
Tokyo, Japon, 113-8519
- Institute of Science Tokyo Hospital_Pediatrics
-
Tokyo, Japon, 157 8535
- National Center for Child Health and Development_Endo and Metabo
-
Tokyo, Japon, 160-8582
- Keio University Hospital_Pediatrics
-
-
-
-
-
Graz, L'Autriche, 8036
- Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
-
Salzburg, L'Autriche, A 5020
- LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
-
Sankt Pölten, L'Autriche, 3100
- LKH St. Poelten, Kinder-und Jugendheilkunde
-
Vöcklabruck, L'Autriche, 4840
- Salzkammergut-Klinikum Vöcklabruck
-
-
Upper Austria
-
Linz, Upper Austria, L'Autriche, 4020
- Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
-
-
-
-
-
Riga, Lettonie, 1004
- Children's Clinical University Hospital
-
-
-
-
-
Bergen, Norvège, 5021
- Haukeland Universitetssykehus, Barneklinikken
-
-
-
-
-
Szczecin, Pologne, 71-252
- SPSK nr 1 im Prof. T Sokolowskiego
-
Warsaw, Pologne, 04-730
- Instytut ''Pomnik - Centrum Zdrowia Dziecka''
-
-
-
-
-
Hull, Royaume-Uni, HU3 2JZ
- Hull Royal Infirmary
-
Liverpool, Royaume-Uni, L12 2AP
- Alder Hey Children's Hospital
-
London, Royaume-Uni, E1 1BB
- Royal London Hospital_London
-
Manchester, Royaume-Uni, M13 9WL
- Royal Manchester Children's Hospital
-
-
-
-
-
Izhevsk, Russie, 426009
- Republic Children's Hospital of Ministry of Health of Udmurt
-
Moscow, Russie, 119435
- Setchenov First Moscow State Medical University
-
Moscow, Russie, 125373
- RMAPE
-
Novosibirsk, Russie, 630048
- Children's clinical city hospital #1
-
Rostov-on-Don, Russie, 344013
- FSBEI of Higher Education "Rostov State Medical University"
-
Saint Petersburg, Russie, 191144
- SPSBHI City Children out-patient clinic #44
-
Samara, Russie, 443079
- Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
-
Tomsk, Russie, 634050
- Siberian State Medical University
-
-
-
-
-
Belgrade, Serbie, 11000
- University Children's Hospital Tirsova
-
Belgrade, Serbie, 11070
- Institute for Mother and Child Health Care of Serbia
-
Kragujevac, Serbie, 34000
- University Clinical Centre Kragujevac
-
Niš, Serbie, 18 000
- Clinical Center in Nis
-
Novi Sad, Serbie, 21000
- Institute for Health Care of Children and Adolescents
-
-
-
-
-
Bern, Suisse, 3010
- Med. Kinder- und Poliklinik
-
Zurich, Suisse, 8032
- Kinderspital Endokrinologie, Zürich
-
-
-
-
-
Bangkok, Thaïlande, 10330
- King Chulalongkorn Memorial hospital-Ped-Endocrinology
-
Bangkok, Thaïlande, 10330
- King Chulalongkorn Memorial hospital_Ped-Endocrinology
-
Bangkok, Thaïlande, 10400
- Phramongkutklao Hospital_Ped-Endo_Pediatrics
-
-
-
-
-
Dnipro, Ukraine, 49100
- Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
-
Kharkiv, Ukraine, 61093
- Kharkiv Regional Children's Clinical Hospital - Endocrinological department
-
Kyiv, Ukraine, 04114
- Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Univ of AL at Birmingham_BRM
-
-
California
-
Orange, California, États-Unis, 92868
- Children's Hosp Of Orange
-
-
Idaho
-
Boise, Idaho, États-Unis, 83712
- St. Luke's Children's Endo
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55454
- Univ of Minnesota M.C.H.
-
Saint Paul, Minnesota, États-Unis, 55102
- Children's Minnesota
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07962
- Goryeb Children's Hospital
-
New Brunswick, New Jersey, États-Unis, 08901
- Rutgers-Rwjms
-
-
New York
-
Garden City, New York, États-Unis, 11530
- NYU Langone Hospital-LI
-
Mineola, New York, États-Unis, 11501
- NYU Langone Hospital-LI
-
New York, New York, États-Unis, 10029
- Icahn Sch of Med-Mt Sinai Hosp
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- CCHMC_Cinc
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Univ Oklahoma Sci Ctr OK City
-
-
Texas
-
Fort Worth, Texas, États-Unis, 76104
- Cook Children's Hospital-Hematology-Oncology
-
-
Washington
-
Tacoma, Washington, États-Unis, 98405
- MultiCare Inst for Res & Innov
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Pre-pubertal children, boys:
- age between 2.5 and 11.0 years at screening.
- testes volume below 4 ml.
-
Pre-pubertal children, girls:
- age between 2.5 and 10.0 years at screening.
- Tanner stage 1 for breast development (no palpable glandular breast tissue).
-
Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).
-
Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.
-
Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.
-
No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.
Exclusion Criteria:
- Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
- Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
- Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
- Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
- Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
- Diagnosis of attention deficit hyperactivity disorder.
- Prior history or presence of malignancy including intracranial tumours.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Somapacitan 0.24 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Expérimental: Somapacitan 0.20 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Expérimental: Somapacitan 0.16 mg/kg/week
Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Somapacitan injected under the skin once a week. |
|
Comparateur actif: Norditropin® 0.035 mg/kg/day
Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Norditropin® injected under the skin once a day. |
|
Comparateur actif: Norditropin® 0.067 mg/kg/day
Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase. |
Norditropin® injected under the skin once a day. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Height Velocity
Délai: Baseline (week 0); week 26
|
Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Ratio of Bone Age Versus Chronological Age
Délai: Baseline (week 0); week 52
|
Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first. |
Baseline (week 0); week 52
|
|
Change in Height Standard Deviation Score (HSDS)
Délai: Baseline (week 0); week 26
|
Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Height Velocity Standard Deviation Score (HVSDS)
Délai: Baseline (week 0); week 26
|
Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Fasting Plasma Glucose
Délai: Baseline (week 0); week 26
|
Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Délai: Baseline (week 0); week 26
|
Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Délai: Baseline (week 0); week 26
|
Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Glycated Haemoglobin (HbA1c)
Délai: Baseline (week 0); week 26
|
Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Délai: Baseline (week 0); week 26
|
Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
|
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Délai: Baseline (week 0); week 26
|
Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first. |
Baseline (week 0); week 26
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NN8640-4245
- 2018 (Subvention/contrat des NIH des États-Unis)
- U1111-1207-9741 (Autre identifiant: World Health Organization (WHO))
- 2018-000232-10 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .